The global Phase 2 study enrolled 275 treatment-naïve patients ... Cash Equivalents and Marketable Securities : $454.7 million at December 31, 2024 compared to $578.1 million at December 31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback